High-dose intravenous melphalan: a review.
BL Samuels, JD Bitran - Journal of clinical oncology, 1995 - ascopubs.org
PURPOSE To review the clinical pharmacology and clinical trials that have used intravenous
(IV) high-dose melphalan (HDM). METHODS We reviewed the mechanism of action, …
(IV) high-dose melphalan (HDM). METHODS We reviewed the mechanism of action, …
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase …
…, D Atanackovic, S Devarakonda, J Bitran… - The Lancet …, 2019 - thelancet.com
Background Pomalidomide and dexamethasone is a standard of care for patients with
multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 …
multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 …
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung
Combination chemotherapy is frequently used in the therapy of advanced non-small-cell
lung cancer (NSCLC), but late complications are rarely recognized because of the short …
lung cancer (NSCLC), but late complications are rarely recognized because of the short …
Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19
…, KE Stockerl-Goldstein, AY Zhou, JD Bitran… - JAMA …, 2023 - jamanetwork.com
Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality and may
be more common in patients with cancer treated with immunotherapy (IO) due to immune …
be more common in patients with cancer treated with immunotherapy (IO) due to immune …
[HTML][HTML] A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR
…, BM Hayes-Lattin, AS Ataergin, JD Bitran… - Biology of Blood and …, 2010 - Elsevier
We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients age ≥18
years undergoing first autologous (n = 837) or myeloablative allogeneic hematopoietic cell …
years undergoing first autologous (n = 837) or myeloablative allogeneic hematopoietic cell …
[PDF][PDF] A review of the abscopal effect in the era of immunotherapy
E Nabrinsky, J Macklis, J Bitran - Cureus, 2022 - cureus.com
The abscopal effect is a systemic immune response mediated by the effects of radiation on
the immune system. This effect has been observed in a number of cancer types in addition to …
the immune system. This effect has been observed in a number of cancer types in addition to …
Erlotinib has moderate single-agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial
…, SK Kelby, D Tsarwhas, S Newman, JD Bitran - Urology, 2009 - Elsevier
OBJECTIVES: To investigate the efficacy and toxicity of single-agent erlotinib in chemotherapy-naive
castration-resistant prostate cancer. METHODS: Eligible patients received erlotinib …
castration-resistant prostate cancer. METHODS: Eligible patients received erlotinib …
Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction
JB Miller, D Variakojis, JD Bitran, DL Sweet, JJ Kinzie… - Cancer, 1981 - Wiley Online Library
Of 107 patients with diffuse histiocytic lymphoma (DHL) seen at the University of Chicago, 14
(13%) were classified as having moderate to marked sclerosis. Three of the 14 (21%) had …
(13%) were classified as having moderate to marked sclerosis. Three of the 14 (21%) had …
Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop.
J Aisner, P Alberto, J Bitran, R Comis… - Cancer treatment …, 1983 - europepmc.org
Many studies in small cell carcinoma of the lung (SCCL) have demonstrated a high response
rate and a potential for cure in a subset of patients. Combination chemotherapy, the …
rate and a potential for cure in a subset of patients. Combination chemotherapy, the …
Prophylactic cranial irradiation in adenocarcinoma of the lung a possible role
RH Jacobs, A Awan, JD Bitran, PC Hoffman, AG Little… - Cancer, 1987 - Wiley Online Library
Seventy‐eight patients with modified Stage II or Stage IIIM0 adenocarcinoma of the lung were
evaluated retrospectively with regard to the impact of prophylactic cranial irradiation (PCI) (…
evaluated retrospectively with regard to the impact of prophylactic cranial irradiation (PCI) (…